Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 13/20 | 0.79 |
| ▸ | LCK | P06239 | 13/20 | 0.79 |
| ▸ | ITK | Q08881 | 13/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | INSR | P06213 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | TEC | P42680 | 1/20 | 0.69 |
| ▸ | TXK | P42681 | 1/20 | 0.69 |
| ▸ | BMX | P51813 | 1/20 | 0.69 |
| ▸ | BTK | Q06187 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138576 | 1.00 | AURKB (0.79) | AURKBLCKITKEGFRINSR | |
| SCHEMBL178942 | 0.89 | AURKB (0.72) | AURKBLCKITKEGFRINSR | |
| SCHEMBL144939 | 0.89 | ITK (1.00) | AURKBLCKITKEGFRINSR | |
| SCHEMBL144940 | 0.89 | ITK (1.00) | AURKBLCKITKEGFRINSR | |
| SCHEMBL143236 | 0.88 | ITK (0.75) | AURKBLCKITKEGFRINSR | |
| SCHEMBL143235 | 0.88 | ITK (0.75) | AURKBLCKITKEGFRINSR | |
| SCHEMBL142315 | 0.87 | ITK (0.79) | AURKBLCKITKEGFRINSR | |
| SCHEMBL142316 | 0.87 | ITK (0.79) | AURKBLCKITKEGFRINSR | |
| SCHEMBL141083 | 0.86 | AURKB (0.77) | AURKBLCKITKEGFRINSR | |
| SCHEMBL141084 | 0.86 | AURKB (0.77) | AURKBLCKITKEGFRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | AURKB 53/4885LCK 189/4885ITK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.